Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

256609.pdf (644.52 KB)
Corrigendum Neoadjuvant endocrine therapy.pdf (257.85 KB)

Document type

Article

Version

Published version

Publication date

2023-01-01

Publication license

cc-by (c) Sirico, Marianna et al., 2023
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/214184

Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.critrevonc.2022.103900

Abstract

Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, it has been proposed as a logical alternative to NACT in patients with HR+/HER2- BC candidate to a neoadjuvant approach. Nevertheless, potential barriers to the widespread use of NET include the heterogeneous nature of patient response coupled with the long duration needed to achieve a clinical response. However, interest in NET has significantly increased in the last decade, owing to more in-depth investigation of several biomarkers for a more adequate patient selection and on-treatment benefit monitoring, such as PEPI score, Ki67 and genomic assays. This review is intended to describe the state-of-the-art regarding NET, its future perspectives and potential integration with molecular biomarkers for the optimal selection of patients, regimen and duration of (neo)adjuvant treatments.

Subject

Càncer de mama, Marcadors bioquímics, Endocrinologia, Tractament adjuvant del càncer

Subject (English)

Breast cancer, Biochemical markers, Endocrinology, Adjuvant treatment of cancer

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

SIRICO, Marianna, et al. Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives. Critical Reviews in Oncology Hematology. 2023. Vol. 181. ISSN 1040-8428. [consulted: 15 of August of 2026]. Available at: https://hdl.handle.net/2445/214184

Export metadata

JSON - METS

Share record